IL10 and COVID-19: The dramatic early rise in IL‐10, canonically classified as an anti‐inflammatory cytokine, appears to be a distinguishing feature of hyperinflammation during severe SARS‐CoV‐2 infection (Lu et al, 2021) and several studies indicate that IL‐10 levels predict poor outcomes in patients with COVID‐19.